Briumvi
Briumvi
BRIUMVI (ublituximab-xiiy) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Administration Information
Briumvi is the anti-CD20 therapy that is administered as a twice yearly 1 hour infusion (after 2 initial loading doses)
Number of yearly treatments: 4
Potential Side Effects
Potential side effects: Most common adverse reactions (greater than/equal to 10%) were infusion reactions such as pyrexia, chills, headache, flu-like illness, tachycardia, nausea, throat irriation, erythema and an anyphylactic reaction. Other common side effects were upper respiratory tract infections.
For a full list of potential side effects, please see the Briumvi website.
Helpful Resources
Patient Forms
Before you attend your first appointment at Omega Health, please make sure to review the documents below. The Patient Consent Form and HIPAA Privacy Authorization Form need to be filled out and signed ahead of your appointment, whereas the Notice of Privacy Practices and Patient Rights and Responsibilities are for reference only. Please contact us if you have any questions!
Patient Consent Form
Print & Sign
HIPAA Privacy Authorization Form
Print & Sign
Notice of Privacy Practice
Read
Patient Rights and Responsibilities
Read
Appointment Lateness and Cancelation
Read
